Barinthus Biotherapeutics (BRNS)
| Bid | 0.61 |
| Market Cap | 28.16M |
| Revenue (ttm) | 14.97M |
| Net Income (ttm) | -61.07M |
| EPS (ttm) | -1.55 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | -0.65 |
| Analyst | Buy |
| Ask | 0.83 |
| Volume | 9,049 |
| Avg. Volume (20D) | 29,767 |
| Open | 0.70 |
| Previous Close | 0.70 |
| Day's Range | 0.70 - 0.73 |
| 52-Week Range | 0.64 - 2.77 |
| Beta | -0.76 |
About BRNS
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, ...
Analyst Forecast
According to 2 analyst ratings, the average rating for BRNS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 328.57% from the latest price.
Stock Forecasts
1 month ago · accessnewswire.com
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th. About...
